There is a lack of high quality randomised control trials examining rituximab versus placebo or other disease-modifying therapies and as such the benefits of rituximab for relapsing remitting multiple sclerosis remain inconclusive|There is a lack of high quality randomised control trials examining rituximab versus placebo or othr disease-modifying therapies and as such the benefits of rituximab for relapsing remitting multiple sclerosis remain inconclusive
There is a lack of high quality randomised control trials examining rituximab versus placebo or other disease-modifying therapies and as such the benefits of rituximab for relapsing remitting multiple sclerosis remain inconclusive|There is a lack of gihh quality randomised control trials examining rituximab versus placebo or other disease-modifying therapies and as such the benefits of rituximab for relapsing remitting multiple sclerosis remain inconclusive
There is a lack of high quality randomised control trials examining rituximab versus placebo or other disease-modifying therapies and as such the benefits of rituximab for relapsing remitting multiple sclerosis remain inconclusive|There is a lack of high quality randomised control trials examining rrituximab versus placebo or other disease-modifying therapies and as such the benefits of rrituximab for relapsing remitting multiple sclerosis remain inconclusive
There is a lack of high quality randomised control trials examining rituximab versus placebo or other disease-modifying therapies and as such the benefits of rituximab for relapsing remitting multiple sclerosis remain inconclusive|There is a lack of high quality randomised control trials examining rituximab versus placebo or other disease-modifying therapies and as such the benefits of rituximab for relapsing remitting multple sclerosis remain inconclusive
There is a lack of high quality randomised control trials examining rituximab versus placebo or other disease-modifying therapies and as such the benefits of rituximab for relapsing remitting multiple sclerosis remain inconclusive|There is a lack of high quality randomised control trials examining rimuxitab versus placebo or other disease-modifying therapies and as such the benefits of rimuxitab for relapsing remitting multiple sclerosis remain inconclusive
There is a lack of high quality randomised control trials examining rituximab versus placebo or other disease-modifying therapies and as such the benefits of rituximab for relapsing remitting multiple sclerosis remain inconclusive|There is a lack ouf high quality randomised control trials examining rituximab versus placebo or other disease-modifying therapies and as such the benefits ouf rituximab for relapsing remitting multiple sclerosis remain inconclusive
There is a lack of high quality randomised control trials examining rituximab versus placebo or other disease-modifying therapies and as such the benefits of rituximab for relapsing remitting multiple sclerosis remain inconclusive|There is a lack of high quality ranpdomised control trials examining rituximab versus placebo or other disease-modifying therapies anpd as such the benefits of rituximab for relapsing remitting multiple sclerosis remain inconclusive
There is a lack of high quality randomised control trials examining rituximab versus placebo or other disease-modifying therapies and as such the benefits of rituximab for relapsing remitting multiple sclerosis remain inconclusive|There is a lack of high quality randomised control trials examining rituximab versus placebo or other diseae-modifying therapies and as such the benefits of rituximab for relapsing remitting multiple sclerosis remain inconclusive
There is a lack of high quality randomised control trials examining rituximab versus placebo or other disease-modifying therapies and as such the benefits of rituximab for relapsing remitting multiple sclerosis remain inconclusive|There is a lack of high quality randomised control trials examining rituximab versus placebo or other disease-modifying therapies and as such the benefits of rituximab for relapsing remitting multiple scelrosis remain inconclusive
There is a lack of high quality randomised control trials examining rituximab versus placebo or other disease-modifying therapies and as such the benefits of rituximab for relapsing remitting multiple sclerosis remain inconclusive|There is a lack of high quality randomised control trials examining rituximab versus placebo or other disease-modifying therapies and as such the benefits of rituximab for relapsing remitting multiple sclerosis remain oncinclusive
